Assyro AI

Orange Book product · Brand (NDA)

COMBOGESIC IV

ACETAMINOPHEN; IBUPROFEN SODIUM

Brand (NDA)NDA 215320RX HIKMA

At a glance

Oct 17, 2023

Approved

Brand (NDA)

Application

Not listed

TE code

10

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Oct 17, 2023

    2 yr 9 mo ago

  2. Today

  3. Exclusivity ends · NP

    New product exclusivity (3 years)

    Oct 17, 2026

    in 4 mo

  4. Patent 11446266 expires

    Listed method-of-use patent (U-3744) expiration.

    Oct 26, 2031

    in 5 yr 5 mo

  5. Patent 11446266 expires

    Listed method-of-use patent (U-3745) expiration.

    Oct 26, 2031

    in 5 yr 5 mo

  6. Patent 11896567 expires

    Listed method-of-use patent (U-3744) expiration.

    Oct 26, 2031

    in 5 yr 5 mo

  7. Patent 11896567 expires

    Listed method-of-use patent (U-3745) expiration.

    Oct 26, 2031

    in 5 yr 5 mo

  8. Patent 12220392 expires

    Listed method-of-use patent (U-4306) expiration.

    Oct 26, 2031

    in 5 yr 5 mo

  9. Patent 12220392 expires

    Listed method-of-use patent (U-4307) expiration.

    Oct 26, 2031

    in 5 yr 5 mo

  10. Patent 11389416 expires

    Listed drug product patent expiration.

    Jul 17, 2035

    in 9 yr 3 mo

  11. Patent 12083087 expires

    Listed method-of-use patent (U-3744) expiration.

    Jul 17, 2035

    in 9 yr 3 mo

  12. Patent 12083087 expires

    Listed method-of-use patent (U-3745) expiration.

    Jul 17, 2035

    in 9 yr 3 mo

  13. Patent 11213498 expires

    Listed drug product patent expiration.

    Jan 14, 2036

    in 9 yr 9 mo

Pharmaceutical detail

Active ingredient

ACETAMINOPHEN; IBUPROFEN SODIUM

Strength

1GM/100ML (10MG/ML);EQ 300MG BASE/100ML (EQ 3MG BASE/ML)

Dosage form

SOLUTION

Route

INTRAVENOUS

TE code

Not listed

Application

NDA 215320

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

  • NPNew product exclusivity (3 years)

    Oct 17, 2026

    in 4 mo

Listed patents (10)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
11446266Oct 26, 2031in 5 yr 5 mo
U-3744
11446266Oct 26, 2031in 5 yr 5 mo
U-3745
11896567Oct 26, 2031in 5 yr 5 mo
U-3744
11896567Oct 26, 2031in 5 yr 5 mo
U-3745
12220392Oct 26, 2031in 5 yr 5 mo
U-4306
12220392Oct 26, 2031in 5 yr 5 mo
U-4307
11389416Jul 17, 2035in 9 yr 3 mo
Product
12083087Jul 17, 2035in 9 yr 3 mo
U-3744
12083087Jul 17, 2035in 9 yr 3 mo
U-3745
11213498Jan 14, 2036in 9 yr 9 mo
Product
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.